BioInvent Using New Screening Platforms To Identify Novel IO Targets

Biotech Boasts Five Compounds Being Examined Across Six Studies

 
• By Chloe Kent

Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.

Curving shelf of books in public library
BioInvent has an extensive antibody library of more than 30 billion human antibody genes • Source: Shutterstock

At Swedish biotech BioInvent, early-stage data on two anti-tumor necrosis factor receptor 2 (TNFR2) antibodies are starting to show promise. Presenting at the annual Society for Immunotherapy for Cancer conference, BioInvent was able to reveal that its candidates BI-1910 and BI-1808 both demonstrated anticancer effects in recent studies.

BI-1910 indicated broad anti-tumor activity in preclinical studies, activating T-cells and natural killer cells and showing anti-tumor activity independent of Fc gamma receptor (FcyR) expression. At the same time, preliminary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo